Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study
Table 3
Association between corticosteroid treatment and the occurrence of AI according to megestrol acetate use.
(a) Megestrol acetate user ()
No-AI ()
AI ()
Age (years)
0.420
Sex (male)
13 (59.1)
25 (53.2)
0.646
BMI (kg/m2)
0.675
Type of corticosteroid
0.335
Prednisolone only
4 (18.2)
14 (29.8)
Dexamethasone only
12 (54.5)
23 (48.9)
Combination
6 (27.3)
10 (21.3)
Cumulative dose of corticosteroids (mg)a,b
41166 (11283–65049)
17088 (7476–33108)
0.016
Cumulative duration of corticosteroid use (days)a
63.0 (31.8–111.0)
36.0 (18.0–64.0)
0.038
Cumulative dose/duration of corticosteroid use (mg/day)a,b
532.8 (280.0–741.3)
366.7 (278.9–700.5)
0.549
(b) Megestrol acetate nonuser ()
No-AI ()
AI ()
Age (years)
0.266
Sex (male)
62 (52.5)
48 (50.5)
0.770
BMI (kg/m2)
0.093
Type of corticosteroid
0.617
Prednisolone only
15 (12.7)
13 (13.7)
Dexamethasone only
72 (61.0)
52 (54.7)
Combination
31 (26.3)
30 (31.6)
Cumulative dose of corticosteroids (mg)b
28132 (12981–61840)
33308 (12800–58035)
0.199
Cumulative duration of corticosteroid use (days)
55.5 (20.0–138.8)
60.0 (28.0–110.0)
0.811
Cumulative dose/duration of corticosteroid use (mg/day)b
519.9 (360.2–770.9)
504.0 (320.1–801.0)
0.772
Data are presented as or median (interquartile range) or (%). a values were generated by Mann-Whitney test. bCorticosteroid doses were expressed in prednisolone equivalents.
